summit astrazeneca - Search News

News

AstraZeneca, Summit

Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports

Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with the matter.

Bloomberg on MSN · 23h

Summit Is in Talks for $15 Billion Partnership With AstraZeneca

AstraZeneca Plc is discussing a partnership deal with Summit Therapeutics Inc. in which it could pay as much as $15 billion over time to license a lung-cancer drug, according to people familiar with the matter.

Seeking Alpha · 5h

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and challenges shaping SMMT's future.

15hon MSN

Why AstraZeneca Stock Got Thumped on Thursday

A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...

22h

AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...

STAT1mon

ASCO 2025: Pfizer, AstraZeneca, Daiichi Sankyo, Summit

At ASCO Day 1, Summit Therapeutics crashes the party again, Pfizer's drug demonstrates "unprecedented" survival rate, and more. ... AstraZeneca’s plenary streak continues: ...

18hon MSN

Why Summit Therapeutics Stock Soared 8% Higher Today

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results